- 1.
Taylor HC. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstetr 1929; 48: 204 – 30.
- 2.
Taylor HC, Alsop WE. Spontaneous regression of peritoneal implantations from ovarian papillary cystadenoma. Am J Cancer 1932; 16: 1305 – 25.
- 3.
Kottmeier HL. The classification and treatment of ovarian tumors. Acta Obstet Gynecol Scand 1952; 31: 313 – 63.
- 4.
Woodruff JD, Novak ER. Papillary serous tumors of the ovary. Am J Obstet Gynecol 1954; 67: 1112 – 26.
- 5.
Ingelman-Sundberg A. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1 – 7.
- 6.
Kottmeier HL, Kolstad P, McGarrity KA. Annual report on results of treatment in gynecologic cancer. Bd. 17. Stockholm: Radiumhemmet, 1973.
- 7.
Serov SF, Scully RE, Sobin LH. International histological classification of tumors, no 9. Histological typing in ovarian tumors. Genève: WHO, 1973.
- 8.
Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Cancer 1973; 31: 1031 – 45.
- 9.
Scully RE. Tumors of the ovary and maldeveloped gonads. Atlas of tumor pathology. Second series. Fascicle 16. Washington D.C.: Armed Forces Institute of Pathology, 1979.
- 10.
Trimble EL, Trimble LC. Epithelial ovarian tumors of low malignant potential. I: Markman M, Hoskins WJ. Cancer of the ovary. New York: Raven Press, 1993.
- 11.
Koonings PP, Campbell K, Mishell DR, Grimes D. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74: 921 – 6.
- 12.
Hoskins PJ. Ovarian tumors of low malignant potential: borderline epithelial ovarian carcinoma. I: Lawton FG, Neijt JP, Swenerton KD, red. Epithelial cancer of the ovary. London: BMJ publishing group, 1995: 112 – 35.
- 13.
Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstetr Gynecol 1971; 37: 1 – 9.
- 14.
Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: histopathologic review of primary ovarian neoplasms diagnosed in the Denver standard metropolitan statistical area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol 1982; 1: 3 – 16.
- 15.
Kaern J, Tropé CG, Abeler VA. A retrospective study of 370 borderline tumors of the ovary treated at The Norwegian Radium Hospital from 1972 to 1982. A review of clinicopathologic features and treatement modalities. Cancer 1993; 71: 1810 – 20.
- 16.
Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Ranimbisson L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993; 4: 289 – 94.
- 17.
Bjørge T, Engeland A, Hansen S, Tropé C. Trends in the incidence of ovarian cancer and borderline tumours in Norway. 1954 – 1993. Int J Cancer 1997; 71: 780 – 6.
- 18.
Auranen A, Grenman S, Mäkinen J, Pukkala E, Sankila R, Salmi T. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol 1996; 144: 548 – 53.
- 19.
Rice LW, Berkowitz RS, Mark SD, Yaunner DL, Lage JM. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol 1990; 39: 195 – 208.
- 20.
Fathalla MF. Incessant ovulation = a factor in ovarian neoplasia? Lancet 1971: 2: 163.
- 21.
Cassagrande JT, Louie EW, Pike MC, Roys S, Henderseon BE. Incessant ovulation and ovarian cancer. Lancet 1979; 2: 170 – 3.
- 22.
Whittemore AS, Wu ML, Pfaffenbarger RS, Sarles DL, Kampert JB, Grosser S et al. Epithelial ovarian cancer and the ability to conceive. Cancer Res 1989; 49: 4047 – 52.
- 23.
Fox H. The concept of borderline malignancy in ovarian tumours: a reappraisal. Curr Top Pathol 1989; 78: 111 – 34.
- 24.
Tasker M, Langley FA. The outlook for women with borderline epithelial tumours of the ovary. Br J Obstet Gynecol 1985; 92: 969 – 75.
- 25.
Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 1986; 68: 338 – 44.
- 26.
Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer 1988; 62: 2212 – 22.
- 27.
Bell DA, Scully RE. Serous borderline tumours of the peritoneum. Am J Surg Pathol 1990; 14: 230 – 9.
- 28.
Bell DA. Ovarian surface epithelial-stromal tumors. Hum Pathol 1991; 22: 750 – 72.
- 29.
Kurman RJ, Trimble CL. The behaviour of serous tumour of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993; 12: 120 – 7.
- 30.
Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20: 1319 – 30.
- 31.
Seidman JD, Kurman R. Subclassification of serous borderline tumours of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331 – 45.
- 32.
Silva EG, Kurman RJ, Russel P, Scully RE. Symposium ovarian tumours of borderline malignancy. Int J Gynecol Pathol 1996; 15: 281 – 302.
- 33.
Silva EG, Tornos C, Zhuang A, Merino MJ, Gershenson DM. Tumors recurrence in stage I ovarian serous low malignant potential neoplasms. Int J Gynecol Pathol 1998; 13: 1 – 6.
- 34.
Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukata T. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990; 38: 90 – 8.
- 35.
Rutgers JL, Scully RE. Ovarian müllerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer 1988; 61: 340 – 8.
- 36.
Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen OE. DNA ploidy, the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 349 – 56.
- 37.
Friedlander ML, Russel P, Taylor IW, Hedley DW, Tattersall M. Flow cytomotric analysis of cellular DNA content as a adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology 1984; 16: 301 – 6.
- 38.
Drescher CW, Flint A, Hopkins MP, Roberts JA. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors. Gynecol Oncol 1993; 48: 242 – 6.
- 39.
Harlow BL, Fuhr JE, McDonald TW, Schwartz S, Bekerlein F, Weiss N. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993; 50: 305 – 9.
- 40.
Klemi PJ, Joensuu H, Kiilholma P, Maenpaa J. Clinical significance of abnormal DNA content in serous ovarian tumors. Cancer 1988; 62: 2005 – 10.
- 41.
Andersen ES, Nielsen K, Nielsen RH. Borderline epithelial tumours of the ovary. Abstract IGCS, International Gynecologic Cancer Society, Third Biennial Meeting Cairns, Australia 1991. Int J Gynecol Cancer 1991; 3: 1.
- 42.
Seidman JD, Norris, HJ, Griffin JL, Hitchcock CL. DNA flow cytometric analysis of serous ovarian tumours of low malignant potential. Cancer 1993; 71: 3947 – 51.
- 43.
Kühn W, Kaufmann M, Feicher GE, Rummel HH, Schmid H, Heberling D. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline tumors. Gynecol Oncol 1989; 33: 360 – 7.
- 44.
Henriksen R. Ovarian carcinogenesis. A study of markers for growth regulatory mechanisms in epithelial ovarian cancer. Doktoravhandling. Uppsala, Sweden: Uppsala University, 1994.
- 45.
Garzetti GG, Ciavattini A, Goteri G. Ki-67 antigen immunostaining (MIB monoclonal antibody) in serous ovarian tumors: index of proliferation activity with prognostic significance. Gynecol Oncol 1995; 56: 169 – 72.
- 46.
Trimble E, Kaern J, Tropé C. Management of borderline tumors of the ovary. I: Ovarian cancer controversies in management. Gershenson DM, McGuire WP, red. New York: Churchill Livingstone, 1998: 195 – 218.
- 47.
Baak JPA, Agrafojo-Blanco A, Kurva PHJ, Langley FA, Boon ME, Lindeman J et al. Quantitation of borderline and malignant mucinous ovarian tumors. Histopathology 1981; 5: 353 – 9.
- 48.
Baak JPA, Fox H, Langley FA, Buckley CH. The prognostic value of morphmetry in ovarian epithelial tumors of borderline malignancy. Int J Gynecol Pathol 1985; 4: 186 – 91.
- 49.
Gotlieb WH, Friedman E, Bar-Sade RB, Kruglikova A, Hirsh-Yechezkel G, Modan B et al. Rates of Jewish ancestral mutation in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998; 13: 995 – 1000.
- 50.
Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 11: 2328 – 30.
- 51.
Wong YF, Cheung TH, Lam SK. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest 1995; 3: 2328 – 30.
- 52.
Kacinski M, Mayer AG, King BL, Carter D, Chambers K. New protein overexpression in benign borderline and malignant ovarian neoplasms. Gynecol Oncol 1992; 44: 245 – 53.
- 53.
Polacarz SV, Hey NA, Stephenson TJ, Hill AS. C-myc oncogene product P62 in ovarian mucinous neoplasm: immunohistochemical study correlated with malignancy. J Clin Pathol 1989; 42: 148 – 52.
- 54.
Mok SH-H, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG et al. Mutation of k-ras protooncogene is associated with histologic subtypes in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489 – 92.
- 55.
Worsley SD, Ponder BA, Davis BR. Overexpression of cyclin D1 in ovarian cancers. Gynecol Oncol 1997; 2: 189 – 95.
- 56.
Lee JH, Kang YS, Park SY, Kim BG, Lee ED, Lee KH et al. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995; 1: 43 – 50.
- 57.
Levine AJ, Perry ME, Chang A. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409 – 16.
- 58.
Hollstein M, Rice K, Greenblatt MS, Souss IT, Fuchs R, Soerlie T et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551 – 5.
- 59.
Momand J, Zambetti GP, Olson DC, Levine AJ. The mdm-2 oncogene product forms a complex with the TP53 protein and inhibits TP53-mediated transactivation. Cell 1992; 69: 1237 – 45.
- 60.
Skomedal H, Kristensen GB, Abeler VM, Börresen-Dale AL, Tropé C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of mdm2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997; 181: 158 – 65.
- 61.
Klemi PJ, Takahasi S, Joensuu H. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994; 13: 228 – 33.
- 62.
Kupryjanczak J, Bell DA, Dimeo D, Beuchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995; 26: 387 – 92.
- 63.
Burchuck A, Kohler MF, Hopkins MP, Humprey PA, Robboy SJ, Rodriquez GC et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994; 52: 232 – 6.
- 64.
Hongxiu J, Lipponen P, Yliskoski M, Syrjanen K, Saarikoi S. Overexpression of p53 in borderline ovarian tumors. Anticancer Res 1995; 15: 1765.
- 65.
Teneriello MG, Ebina M, Linnoila RI, Henry JD, Park RC, Birren MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasm. Cancer Res 1993; 53: 3103 – 8.
- 66.
Zheng J, Benedict WF, Xu HJ, Hu SH, Kim TM, Velicescu KM et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995; 87: 1146 – 53.
- 67.
Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, NG SW et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998; 18: 2381 – 7.
- 68.
Lau CC, Wong KK, Rock CC, Berkowitz RS, Mok SC. Identification of differentially expressed gene DOC-2 in human ovarian cancer. Proc Annu Meet Am Assoc Cancer Res 1997; 38: 484.
- 69.
Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given F et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 2752 – 6.
- 70.
Chambers JT, Merino MJ, Kohorn EI, Schwartz PE. Borderline ovarian tumors. Am J Obstet Gynecol 1988; 159: 1088 – 94.
- 71.
Leake JF, Currie JL, Rosenschein NB, Woodruff TD. Long term follow-up of ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47: 150 – 8.
- 72.
Lim-Tan SK, Cajigas HG, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72: 775 – 81.
- 73.
Leake JF, Rader JS, Woddruff JD, Rosenscheim NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991; 42: 124 – 30.
- 74.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124 – 32.
- 75.
NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening treatment, and follow-up. JAMA 1995; 273: 491.
- 76.
Creaseman WT, Park R, Norris H, Disaia PJ, Morrow PA, Hreshchynshyn MM. Stage I borderline ovarian tumors. Obstet Gynecol 1982; 59: 93 – 6.
- 77.
Young RC, Walton LA, Ellenberg SS, Homesley H, Wilbanks G, Decker G et al. Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two randomized trials. N Engl J Med 1990; 322: 1021 – 7.
- 78.
Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51: 236 – 43.
- 79.
Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990; 65: 578 – 85.
- 80.
Sutton GP, Bundy GN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41: 230 – 3.
- 81.
Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnoses in Norway between 1954 and 1993. Int J Cancer 1998; 75: 663 – 70.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.